Description: IN04, also know as Methyl 3-(2-((5-(3,5-dimethoxyphenyl)-1,3,4-oxadiazol-2-yl)thio)acetamido)benzoate, is a novel and potent inhibitor of Leucine rich repeat kinase 1 (LRRK1), suppressing osteoclasts (OC) function with no effect on OC formation. IN04 inhibits LRRK1 by binding to the active site of the kinase domain but not the ROC domain. LRRK1 plays a critical role in regulating OC function and peak bone mass. Therefore, LRRK1 is a novel drug target for alternative anti-resorptive drugs to treat osteoporosis and osteoporotic fractures.
References: Aging (Albany NY) . 2019 May 21;11(10):3250-3261. doi: 10.18632/aging.101977.